|
|
|
Last Updated: Nov 18, 2006 - 1:55:25 PM |
Latest Research
:
Clinical Trials
Start of Second Phase III Trial in MS Neuropathic Pain
GW Pharmaceuticals plc (AIM: GWP) announces the start of a second pivotal Phase III trial in people with multiple sclerosis (MS) suffering from central neuropathic pain. The first patient has now been enrolled in the study.
Aug 9, 2006 - 2:46:00 PM
[ Visit Website ]
Latest Research
:
Clinical Trials
RISUG (Reversible Inhibition of Sperm Under Guidance) Trial to recruit more volunteers
The trial is studying a new male contraceptive, RISUG (Reversible Inhibition of Sperm Under Guidance): a reversible, nonhormonal contraceptive that provides 10 or more years of protection after a 10-15 minute procedure. Researchers received approval this week to begin enrolling additional study volunteers, after a delay of nearly four years.
Mar 31, 2006 - 12:43:00 PM
[ Visit Website ]
Latest Research
:
Clinical Trials
EU clinical trials directive is threatening future of cancer research
A new European directive is threatening the future of cancer research in Europe, warn experts in this week�s BMJ. The EU clinical trials directive, implemented in 2004, was intended to protect patients and improve research standards. But many investigators were worried that the labour intensive, bureaucratic, and expensive endeavour of running a clinical trial would become worse under the new rules. In particular, academic researchers funded by grants, who have so far performed most cancer trials, were worried that their resources might no longer suffice to meet the requirements of the new directive.
Mar 4, 2006 - 3:14:00 PM
[ Visit Website ]
Latest Research
:
Clinical Trials
Lessons from natalizumab fast tracking in multiple sclerosis
Concerns over the fast tracking of new drugs for commercial licensing are raised by a senior doctor in this week�s BMJ. It follows approval of natalizumab, a new drug for multiple sclerosis, and its recall three months later, after three trial patients developed a life threatening condition while being treated. Natalizumab was licensed by the US Food and Drug Administration in 2004 for use in relapsing multiple sclerosis on the basis of short term results from two unpublished trials. The FDA granted approval before final trial and cumulative safety data were available. Natalizumab was predicted to be the leading drug for multiple sclerosis, with estimated annual sales in excess of $2bn.
Feb 17, 2006 - 7:05:00 PM
[ Visit Website ]
Latest Research
:
Clinical Trials
First human trial of recombinant ricin vaccine completed
Scientists have completed the first human clinical trial of a recombinant vaccine for the deadly toxin ricin - a potential bioterror threat � and the results indicate the vaccine is safe and effective in eliciting ricin-neutralizing antibodies, the UT Southwestern Medical Center researchers report.
Jan 31, 2006 - 7:54:00 PM
[ Visit Website ]
Latest Research
:
Clinical Trials
New stem cell study seeks to prevent heart failure
University of Rochester Medical Center researchers today announced the launch of a study that will examine whether transplanted stem cells can be safely used to treat damaged heart muscle in patients just after their first heart attack. As part of the fast emerging science of regenerative medicine, labs worldwide are attempting to replace damaged tissue with new cells, much in the same way as salamanders re-grow limbs.
Jan 24, 2006 - 6:12:00 PM
[ Visit Website ]
Latest Research
:
Clinical Trials
Electronic health record-based clinical trial alert system increased recruitment rates
An electronic health record-based clinical trial alert system increased recruitment rates and physicians' participation in an ongoing clinical trial, according to a study in the October 24 issue of the Archives of Internal Medicine, one of the JAMA/Archives journals.
Oct 25, 2005 - 5:16:00 AM
[ Visit Website ]
Latest Research
:
Clinical Trials
Study of New, Non-Growth Hormone Treatment for Short Stature
Rush University Medical Center is participating in a clinical trial to evaluate the potential benefit of the first major innovation in 20 years for the treatment of growth failure. The drug, called Increlex, was approved by the FDA August 31 for the most severe form of short stature due to a deficiency of Insulin-like Growth Factor-1 (IGF-1). Ongoing trials will determine if the drug may be used for less severe growth disease.
Sep 13, 2005 - 9:05:00 PM
[ Visit Website ]
<< prev
next >>
|
|
|
|
Health  |
Gathering information about food is not top priority for individuals with high metabolisms
|
NIH renews funding for University of Maryland vaccine research
|
DHA-enriched formula in infancy linked to positive cognitive outcomes in childhood
|
New IOM report lays out plan to determine effectiveness of obesity prevention efforts
|
Vitamin D supplementation may delay precocious puberty in girls
|
Study: Pedometer program helps motivate participants to sit less, move more
|
Fish oil may stall effects of junk food on brain
|
Intake of low energy dense food better than skipping meals
|
Inaugural IOF Olof Johnell Science Award presented to Professor Harry Genant
|
Molecular hub links obesity, heart disease to high blood pressure
|
| | Healthcare |
Healthcare experts from UK and India meet at the UK Parliament to discuss ways to improve health care in India, UK
|
Flu pandemic infected one in five
|
Stigma preventing leprosy-cured from getting jobs
|
Measles, Mumps make a comeback in US
|
Melinda Gates calls on Akhilesh Yadav
|
'Movies, TV impact tobacco users more than newspapers'
|
Rockland to open three new hospitals in NCR
|
Spice Global enters healthcare business with hospital in Delhi
|
Delhi to expedite recruitment of doctors
|
India adds spice to US life, keeps it healthy
|
| | Latest Research |
How do consumers see a product when they hear music?
|
Drug activates virus against cancer
|
Bone loss associated with increased production of ROS
|
Sound preconditioning prevents ototoxic drug-induced hearing loss in mice
|
Crystal methamphetamine use by street youth increases risk of injecting drugs
|
Johns Hopkins-led study shows increased life expectancy among family caregivers
|
Moderate to severe psoriasis linked to chronic kidney disease, say experts
|
Licensing deal marks coming of age for University of Washington, University of Alabama-Birmingham
|
Simple blood or urine test to identify blinding disease
|
Physician job satisfaction driven by quality of patient care
|
| | Medical News |
NHRC issues notice to Kerala over infant deaths
|
Advanced breast cancer detecting machine comes to India
|
'Dispel myths about vitiligo'
|
NHRC summons Odisha chief secretary
|
Woman dies of swine flu in UP
|
Maharashtra, GE to modernise rural health care
|
Hypertension: India's silent killer
|
Need cautious effort to eradicate polio: Experts
|
Ayurveda experts develop online personalised health regimen
|
Soon a detailed study on 'diabesity': Doctors
|
| | Special Topics |
MPs express anguish at Delhi gang-rape, Shinde assures fast trial
|
Worrying rise in number of medical students in prostitution over last 10 years
|
Behold India's unfolding democratic revolution
|
Chinese woman cuts open her belly to save surgery cost
|
Improved Sense of Smell Produced Smarter Mammals
|
Two-year-old world's first to have extra DNA strand
|
172,155 kidney stones removed from one patient!
|
'Primodial Soup' theory for origin of life rejected in paper
|
Human species could have killed Neanderthal man
|
History, geography also seem to shape our genome
|
|
|
